<DOC>
	<DOCNO>NCT00355654</DOCNO>
	<brief_summary>The purpose study provide data safety immunogenicity Pediacel® allow use fourth dose administer 11-18 month old toddler time Prevenar® . Primary Objective : To evaluate safety Pediacel® booster dose co-administered Prevenar® toddler 11-18 month age . Secondary Objectives : - To describe incidence rate severe fever within four day post-vaccination - To describe antibody response antigens subgroup subject baseline post-vaccination .</brief_summary>
	<brief_title>Study Compare Booster Vaccination With Pediacel® Infanrix® Hexa When Both Are Co-Administered With Prevenar®</brief_title>
	<detailed_description />
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Toddlers 1118 month age ( 11th month birthday one day prior 19th month birthday ) previously receive primary immunisation series hexavalent vaccine ( consist three dos diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B Haemophilus influenza type b combine vaccine administer within first 6 month life ) Informed consent form sign parent legal guardian Parents legal guardian able read write local language Parents legal guardian able attend schedule visit comply study procedure . Presence fever ( defined rectal body temperature ≥ 38.0°C ) report within last 72 hour Moderate severe acute illness without fever Participation another clinical trial 30 day precede study vaccination Planned participation another clinical trial present study period Immunisation pneumococcal vaccine prior study vaccination plan participation study Received 3 dos hexavalent vaccine prior study vaccination Received vaccination 30 day precede trial History serological/microbiologicallyconfirmed diagnosis infection due pertussis , tetanus , diphtheria , poliomyelitis , hepatitis B , Haemophilus influenzae type b and/or Streptococcus pneumoniae Congenital acquire humoral/cellular immunodeficiency immunosuppressive therapy longterm systemic corticosteroid therapy ( ≥ 2 mg/kg/day prednisone equivalent ≥ 14 day 30 day prior study vaccination ) Systemic local hypersensitivity study vaccine component ( include neomycin , streptomycin , polymyxin B formaldehyde ) History lifethreatening reaction ( encephalopathy , HypotonicHyporesponsive Episode ( HHE ) , rectal body temperature ≥ 40.0°C , convulsion without fever ) vaccine contain component study vaccine Blood bloodderived product ( immunoglobulin ) receive 3 month prior study vaccination Known HIV seropositivity Known thrombocytopenia bleed disorder contraindicate intramuscular vaccination History encephalopathy , seizures progressive , evolve unstable neurological condition Clinically significant finding review system might interfere study vaccination , opinion Investigator , would interfere evaluation study vaccine/objectives pose health risk subject .</criteria>
	<gender>All</gender>
	<minimum_age>11 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
	<keyword>Hepatitis B</keyword>
</DOC>